Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation, Biologic therapy.

Reed Neurological Research Center, Los Angeles, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Los Angeles, CA
Treatments:Chemotherapy, Radiation, Biologic therapyHospital:Reed Neurological Research Center
Drugs:Journal:Link
Date:Jan 2011

Description:

Patients:
This study involved 70 patients with newly diagnosed glioblastoma multiforme. The median age was 57.4 years and 56% of patients were male.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab (a monoclonal antibody that blocks cancer cell growth by targeting the vascular endothelial growth factor (VEGF) protein), the chemotherapeutic agent temozolomide, and radiation.

Toxicities:
The maximum toxicity level reported was of grade 4. Grade 3-4 effects included fatigue (14 cases), venous thrombosis/pulmonary embolism (13), and gastrointestinal bleeding or perforation (2 each).

Results:
The median progression-free survival was 13.6 months and the median overall survival was 19.6 months.

Support:
This study was partially supported by Genentech, makers of bevacizumab (trade name: Avastin).

Correspondence: Dr. Albert Lai; email: [email protected]



Back